Haleon plc:
Director/PDMR Shareholding
22 November 2024:
Haleon plc (the "Company" or "Haleon")
(LSE/NYSE:HLN) today announces notification and public disclosure
in accordance with the requirements of The UK Market Abuse
Regulation of Transactions by a Person Discharging Managerial
Responsibilities ("PDMR").
On 21 November 2024, Dawn Allen,
Chief Financial Officer, received the vesting of an award of Haleon
Ordinary Shares under the Haleon Share Value Plan. The award was
granted as part of her remuneration arrangements upon joining
Haleon, to compensate for forfeited incentives from her previous
employment.
Immediately following vesting
74,678.928393 Ordinary
Shares were sold to cover tax obligations at a price of
£3.718 per share,
with the remaining 83,974.071607 Ordinary Shares retained subject
to a two-year holding period.
The award is subject to malus and
clawback provisions.
Further details are set out in the
below notification, made in accordance with the requirements of The
UK Market Abuse Regulations.
|
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
|
a)
|
Name
|
Dawn Allen
|
|
|
2
|
Reason for the notification
|
|
|
a)
|
Position/status
|
Chief Financial Officer
|
|
|
b)
|
Initial notification
/Amendment
|
Initial
Notification
|
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction
monitor
|
|
|
a)
|
Name
|
Haleon plc
|
|
|
b)
|
LEI
|
549300PSB3WWEODCUP19
|
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
|
a)
|
Description of the financial
instrument, type of instrument
|
Ordinary Shares of £0.01
each
|
|
|
|
|
|
|
Identification
code
|
GB00BMX86B70
|
|
|
|
|
|
|
b)
|
Nature of the
transaction
|
Acquisition of Ordinary Shares in
respect of the Haleon plc Share Value Plan (Buyout
award).
|
|
|
c)
|
Price(s) and
volume(s)
|
|
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
|
|
Nil
|
158,653
|
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
|
|
|
|
|
|
- Aggregated volume
|
N/A
|
|
|
|
|
|
|
- Price
|
|
|
|
|
|
|
|
e)
|
Date of the
transaction
|
21 November 2024
|
|
|
f)
|
Place of the
transaction
|
Outside a trading venue
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
|
Ordinary Shares of £0.01
each
|
|
|
|
|
Identification
code
|
GB00BMX86B70
|
|
|
|
|
b)
|
Nature of the
transaction
|
Automatic disposal of Ordinary
Shares resulting from the Haleon plc Share Value Plan (Buyout
award) vesting to cover tax liabilities.
|
|
c)
|
Price(s) and
volume(s)
|
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
|
£3.718
|
74,678.928393
|
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
|
|
|
|
- Aggregated volume
|
N/A
|
|
|
|
|
- Price
|
|
|
|
|
|
e)
|
Date of the
transaction
|
21 November 2024
|
|
f)
|
Place of the
transaction
|
London Stock
Exchange (XLON)
|
|
|
|
|
|
|
|
| |
Amanda Mellor
Company Secretary
About Haleon
Haleon (LSE/NYSE: HLN) is a global
leader in consumer health, with a purpose to deliver better
everyday health with humanity. Haleon's product portfolio spans
five major categories - Oral Health, Pain Relief, Respiratory
Health, Digestive Health and Other, and Vitamins, Minerals and
Supplements (VMS). Its long-standing brands - such as Advil,
Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident,
parodontax and Centrum - are built on trusted science, innovation
and deep human understanding.
For more information, please
visit www.haleon.com.